Scholarlink

<p>The progression of non-small cell lung cancer (NSCLC) is driven by metabolic plasticity and evasion of apoptotic surveillance, mechanisms that remain incompletely understood. Here, through integrated transcriptomic–metabolomic profiling, molecular interaction mapping, and functional validation, we unveiled a dual regulatory mechanism governed by the MTHFR/SLC25A26 axis that suppresses NSCLC. Clinical cohort analyses revealed concurrent downregulation of MTHFR and SLC25A26 in NSCLC tissues, which strongly correlated with poor prognosis. Mechanistically, MTHFR directly binds and stabilizes SLC25A26, whereas SLC25A26 accelerates SHMT2 degradation via the ubiquitin-proteasome pathway and concurrently suppresses AKT-driven MYB transcriptional activation. This coordinated disruption of serine/one-carbon metabolism and oncogenic signaling significantly inhibited tumor growth in patient-derived xenograft models. Crucially, we identified SLC25A26 as a mitochondrial transporter-ubiquitin adapter hybrid that destabilizes SHMT2 through ubiquitination, whereas its interaction with MTHFR prevents metabolic dysregulation induced by the C677T mutation. Our findings establish the MTHFR/SLC25A26 axis as a master regulator of metabolic–transcriptional crosstalk, providing a therapeutic framework for targeting enzyme stability and kinase signaling in NSCLC treatment.</p><p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

MTHFR functions as a metabolic checkpoint in NSCLC through SLC25A26-mediated SHMT2 inhibition

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月1日

查看全文
  • Lan li,
  • YiRan Yang,
  • ShiQing Wang,
  • Dan Li,
  • ChuMao Chen,
  • XinMei Mu,
  • JiaXin Wu,
  • Jin Yuan

摘要

The progression of non-small cell lung cancer (NSCLC) is driven by metabolic plasticity and evasion of apoptotic surveillance, mechanisms that remain incompletely understood. Here, through integrated transcriptomic–metabolomic profiling, molecular interaction mapping, and functional validation, we unveiled a dual regulatory mechanism governed by the MTHFR/SLC25A26 axis that suppresses NSCLC. Clinical cohort analyses revealed concurrent downregulation of MTHFR and SLC25A26 in NSCLC tissues, which strongly correlated with poor prognosis. Mechanistically, MTHFR directly binds and stabilizes SLC25A26, whereas SLC25A26 accelerates SHMT2 degradation via the ubiquitin-proteasome pathway and concurrently suppresses AKT-driven MYB transcriptional activation. This coordinated disruption of serine/one-carbon metabolism and oncogenic signaling significantly inhibited tumor growth in patient-derived xenograft models. Crucially, we identified SLC25A26 as a mitochondrial transporter-ubiquitin adapter hybrid that destabilizes SHMT2 through ubiquitination, whereas its interaction with MTHFR prevents metabolic dysregulation induced by the C677T mutation. Our findings establish the MTHFR/SLC25A26 axis as a master regulator of metabolic–transcriptional crosstalk, providing a therapeutic framework for targeting enzyme stability and kinase signaling in NSCLC treatment.